Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Jianmin Pharmaceutical Group

SHSE:600976
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
600976
SHSE
CN¥2B
Market Cap
  1. Home
  2. CN
  3. Pharmaceuticals & Biotech
Company description

Jianmin Pharmaceutical Group Co., Ltd. manufactures and sells Chinese medicines in China. The last earnings update was 167 days ago. More info.


Add to Portfolio Compare Print
600976 Share Price and Events
7 Day Returns
0.4%
SHSE:600976
0.3%
CN Pharmaceuticals
-0.1%
CN Market
1 Year Returns
-24.2%
SHSE:600976
2.1%
CN Pharmaceuticals
-9.3%
CN Market
600976 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Jianmin Pharmaceutical Group (600976) 0.4% -9.5% -13% -24.2% -48.8% -57.1%
CN Pharmaceuticals 0.3% -3.8% 5.7% 2.1% 0.1% -4.7%
CN Market -0.1% -10.6% -6.3% -9.3% -16.2% -26.5%
1 Year Return vs Industry and Market
  • 600976 underperformed the Pharmaceuticals industry which returned 2.1% over the past year.
  • 600976 underperformed the Market in China which returned -9.3% over the past year.
Price Volatility
600976
Industry
5yr Volatility vs Market

600976 Value

 Is Jianmin Pharmaceutical Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Jianmin Pharmaceutical Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Jianmin Pharmaceutical Group.

SHSE:600976 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in CNY CN¥ .200000
Payout Ratio Company Filings (2019-09-30) 3837.2%
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SHSE:600976
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.686 (1 + (1- 25%) (0%))
0.803
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.803 * 6.33%)
8.28%

Discounted Cash Flow Calculation for SHSE:600976 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Jianmin Pharmaceutical Group is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

SHSE:600976 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= CN¥0.2 / (8.28% - 3.2%)
CN¥3.93
SHSE:600976 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥3.93
Current discount Discount to share price of CN¥15.54
= -1 x (CN¥15.54 - CN¥3.93) / CN¥3.93
-295%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Jianmin Pharmaceutical Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Jianmin Pharmaceutical Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Jianmin Pharmaceutical Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SHSE:600976 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CNY CN¥0.53
SHSE:600976 Share Price ** SHSE (2020-04-03) in CNY CN¥15.54
China Pharmaceuticals Industry PE Ratio Median Figure of 157 Publicly-Listed Pharmaceuticals Companies 30.57x
China Market PE Ratio Median Figure of 3,197 Publicly-Listed Companies 32.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Jianmin Pharmaceutical Group.

SHSE:600976 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SHSE:600976 Share Price ÷ EPS (both in CNY)

= 15.54 ÷ 0.53

29.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jianmin Pharmaceutical Group is good value based on earnings compared to the CN Pharmaceuticals industry average.
  • Jianmin Pharmaceutical Group is good value based on earnings compared to the China market.
Price based on expected Growth
Does Jianmin Pharmaceutical Group's expected growth come at a high price?
Raw Data
SHSE:600976 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 29.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
China Pharmaceuticals Industry PEG Ratio Median Figure of 55 Publicly-Listed Pharmaceuticals Companies 1.59x
China Market PEG Ratio Median Figure of 1,273 Publicly-Listed Companies 1.27x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Jianmin Pharmaceutical Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Jianmin Pharmaceutical Group's assets?
Raw Data
SHSE:600976 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CNY CN¥7.44
SHSE:600976 Share Price * SHSE (2020-04-03) in CNY CN¥15.54
China Pharmaceuticals Industry PB Ratio Median Figure of 174 Publicly-Listed Pharmaceuticals Companies 2.62x
China Market PB Ratio Median Figure of 3,691 Publicly-Listed Companies 2.26x
SHSE:600976 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SHSE:600976 Share Price ÷ Book Value per Share (both in CNY)

= 15.54 ÷ 7.44

2.09x

* Primary Listing of Jianmin Pharmaceutical Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Jianmin Pharmaceutical Group is good value based on assets compared to the CN Pharmaceuticals industry average.
X
Value checks
We assess Jianmin Pharmaceutical Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Jianmin Pharmaceutical Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

600976 Future Performance

 How is Jianmin Pharmaceutical Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jianmin Pharmaceutical Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Jianmin Pharmaceutical Group expected to grow at an attractive rate?
  • Unable to compare Jianmin Pharmaceutical Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Jianmin Pharmaceutical Group's earnings growth to the China market average as no estimate data is available.
  • Unable to compare Jianmin Pharmaceutical Group's revenue growth to the China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SHSE:600976 Future Growth Rates Data Sources
Data Point Source Value (per year)
China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 23%
China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 18.2%
China Market Earnings Growth Rate Market Cap Weighted Average 20.9%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SHSE:600976 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SHSE:600976 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
SHSE:600976 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-09-30 2,402 35 82
2019-06-30 2,199 41 80
2019-03-31 2,183 73 79
2018-12-31 2,161 64 81
2018-09-30 2,188 92 91
2018-06-30 2,311 130 100
2018-03-31 2,625 93 102
2017-12-31 2,712 35 91
2017-09-30 2,748 72 81
2017-06-30 2,677 54 71
2017-03-31 2,315 41 59
2016-12-31 2,364 114 65

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Jianmin Pharmaceutical Group is high growth as no earnings estimate data is available.
  • Unable to determine if Jianmin Pharmaceutical Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SHSE:600976 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Jianmin Pharmaceutical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:600976 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
SHSE:600976 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-09-30 0.53
2019-06-30 0.51
2019-03-31 0.52
2018-12-31 0.53
2018-09-30 0.60
2018-06-30 0.66
2018-03-31 0.66
2017-12-31 0.59
2017-09-30 0.52
2017-06-30 0.46
2017-03-31 0.39
2016-12-31 0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Jianmin Pharmaceutical Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Jianmin Pharmaceutical Group is trading at Jianmin Pharmaceutical Group'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Jianmin Pharmaceutical Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Jianmin Pharmaceutical Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Jianmin Pharmaceutical Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

600976 Past Performance

  How has Jianmin Pharmaceutical Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Jianmin Pharmaceutical Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Jianmin Pharmaceutical Group's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Jianmin Pharmaceutical Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Jianmin Pharmaceutical Group's 1-year earnings growth is negative, it can't be compared to the CN Pharmaceuticals industry average.
Earnings and Revenue History
Jianmin Pharmaceutical Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Jianmin Pharmaceutical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SHSE:600976 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 2,402.17 81.82 747.66 28.27
2019-06-30 2,198.84 79.68 695.87 29.94
2019-03-31 2,183.32 79.35 667.74 29.32
2018-12-31 2,161.48 81.22 670.62 25.62
2018-09-30 2,187.90 91.13 740.06 26.96
2018-06-30 2,311.49 100.11 721.38 34.57
2018-03-31 2,624.73 102.00 682.54 29.75
2017-12-31 2,711.50 90.78 646.65 24.08
2017-09-30 2,747.73 80.93 603.56 15.30
2017-06-30 2,676.90 70.83 578.53
2017-03-31 2,315.20 59.28 542.61
2016-12-31 2,363.65 64.66 509.38
2016-09-30 2,494.51 69.21 455.84
2016-06-30 2,430.08 80.11 447.95
2016-03-31 2,448.56 83.06 424.18
2015-12-31 2,281.22 85.50 404.14
2015-09-30 1,952.72 86.09 384.37
2015-06-30 1,859.60 102.07 324.20
2015-03-31 1,747.77 113.82 316.60
2014-12-31 1,753.49 115.97 327.69
2014-09-30 1,684.98 117.92 313.77
2014-06-30 1,716.00 108.08 331.89
2014-03-31 1,866.56 98.35 339.42
2013-12-31 1,992.39 95.90 336.07
2013-09-30 1,945.26 98.71 324.37
2013-06-30 1,879.84 91.87 312.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Jianmin Pharmaceutical Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Jianmin Pharmaceutical Group used its assets less efficiently than the CN Pharmaceuticals industry average last year based on Return on Assets.
  • Jianmin Pharmaceutical Group's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Jianmin Pharmaceutical Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Jianmin Pharmaceutical Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

600976 Health

 How is Jianmin Pharmaceutical Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Jianmin Pharmaceutical Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Jianmin Pharmaceutical Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jianmin Pharmaceutical Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Jianmin Pharmaceutical Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Jianmin Pharmaceutical Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Jianmin Pharmaceutical Group Company Filings, last reported 6 months ago.

SHSE:600976 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1,189.99 0.00 402.82
2019-06-30 1,172.20 0.00 445.01
2019-03-31 1,173.58 0.00 449.38
2018-12-31 1,145.07 0.00 460.41
2018-09-30 1,136.42 0.00 87.15
2018-06-30 1,124.81 0.00 449.25
2018-03-31 1,126.74 0.00 163.40
2017-12-31 1,107.45 0.00 430.70
2017-09-30 1,088.93 25.00 122.15
2017-06-30 1,064.57 32.68 427.05
2017-03-31 1,049.45 34.93 240.90
2016-12-31 1,031.35 9.67 462.99
2016-09-30 1,023.09 0.00 359.01
2016-06-30 1,008.12 0.00 397.01
2016-03-31 1,020.45 30.00 348.26
2015-12-31 997.36 30.00 456.30
2015-09-30 984.98 30.00 39.96
2015-06-30 990.70 30.00 474.16
2015-03-31 1,028.82 30.00 520.53
2014-12-31 1,002.03 30.00 495.16
2014-09-30 986.61 30.00 259.54
2014-06-30 944.92 30.00 407.61
2014-03-31 969.13 0.00 211.45
2013-12-31 940.46 0.00 364.52
2013-09-30 926.32 0.00 147.33
2013-06-30 904.85 0.00 227.31
  • Jianmin Pharmaceutical Group has no debt.
  • Jianmin Pharmaceutical Group has no debt compared to 5 years ago when it was 3%.
  • Jianmin Pharmaceutical Group has no debt, it does not need to be covered by operating cash flow.
  • Jianmin Pharmaceutical Group has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Jianmin Pharmaceutical Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Jianmin Pharmaceutical Group has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

600976 Dividends

 What is Jianmin Pharmaceutical Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.29%
Current annual income from Jianmin Pharmaceutical Group dividends.
If you bought CN¥2,000 of Jianmin Pharmaceutical Group shares you are expected to receive CN¥26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Jianmin Pharmaceutical Group's pays a higher dividend yield than the bottom 25% of dividend payers in China (0.46%).
  • Jianmin Pharmaceutical Group's dividend is below the markets top 25% of dividend payers in China (2.03%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SHSE:600976 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 137 Stocks 1.2%
China Market Average Dividend Yield Market Cap Weighted Average of 2588 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SHSE:600976 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
SHSE:600976 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2019-05-28 0.200 1.196
2018-05-25 0.200 1.152
2017-05-03 0.100 0.399
2016-05-24 0.200 0.665
2015-04-29 0.380 1.299
2014-03-27 0.380 1.461
2013-05-02 0.380 1.717
2013-03-15 0.380 2.300
2012-05-08 0.400 2.390
2011-06-07 0.300 1.874
2010-02-26 0.150 0.831
2009-04-20 0.050 0.468

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Jianmin Pharmaceutical Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.7x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Jianmin Pharmaceutical Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Jianmin Pharmaceutical Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Jianmin Pharmaceutical Group has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

600976 Management

 What is the CEO of Jianmin Pharmaceutical Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Jianmin Pharmaceutical Group has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Jianmin Pharmaceutical Group management team in years:

4.4
Average Tenure
  • The tenure for the Jianmin Pharmaceutical Group management team is about average.
Management Team

Shao Quan Wang

TITLE
Chief Financial Officer
COMPENSATION
CN¥60K
TENURE
4.4 yrs

Zhenbo Hu

TITLE
Vice President
COMPENSATION
CN¥411K
TENURE
5.7 yrs

Zhongjiang Bu

TITLE
Vice President
COMPENSATION
CN¥377K
TENURE
4.3 yrs

Mingde Du

TITLE
Secretary of The Board
COMPENSATION
CN¥400K
Board of Directors

Qin He

TITLE
Chairman
AGE
58

Guo Ying Ding

TITLE
Chairman of Board of Supervisors
AGE
54
TENURE
8.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess Jianmin Pharmaceutical Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Jianmin Pharmaceutical Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

600976 News

Simply Wall St News

600976 Company Info

Description

Jianmin Pharmaceutical Group Co., Ltd. manufactures and sells Chinese medicines in China. It offers pediatric drugs under the Jianmin, Longmu, and Yekaitai brands. The company is based in Wuhan, China.

Details
Name: Jianmin Pharmaceutical Group Co., Ltd.
600976
Exchange: SHSE
Founded:
CN¥2,383,814,244
153,398,600
Website: http://www.whjm.com
Address: Jianmin Pharmaceutical Group Co., Ltd.
No. 484 Parrot Avenue,
Hanyang District,
Wuhan,
Hubei Province, China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SHSE 600976 Domestic Shares Shanghai Stock Exchange CN CNY 19. Apr 2004
XSSC 600976 Domestic Shares Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect CN CNY 19. Apr 2004
Number of employees
Current staff
Staff numbers
1,972
Jianmin Pharmaceutical Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 14:34
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2018/03/27
Last earnings filing: 2019/10/22
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.